executive summary

Pfizer trades at ~8x adjusted earnings with a 6% dividend yield, offering post-COVID normalization upside through Seagen integration and cost restructuring. Conviction 30/100 reflects significant model uncertainty.

recommendation

Long

12m price target

$34.00

+28% from $26.58

intrinsic value

$32.30

+22% vs spot

thesis confidence

30/100

low

Kill Criteria — Position Closure Triggers

Seagen Synergy Miss: <$3B by 2027 vs $4B guided (25% buffer, 35% probability) — impairs goodwill, forces guidance cut
Dividend Coverage Failure: FCF/dividend <0.9x vs ~1.0x current ($9.08B/$9.08B) — 10% margin, 30% probability
Goodwill Impairment Event: >$5B write-down of $71.26B carrying value — 7% of goodwill, 25% probability

Position sizing: 0-1% at 30/100 conviction; full exit if any two triggers activate simultaneously.

key metrics snapshot

snapshot

price

$26.97

market cap

$151.1B

trailing p/e

19.5x

gross margin

74.3%

net margin

12.4%

revenue (fy2025)

$62.58B

fcf yield

6.0%

goodwill/assets

34.2%

How to Read This Report

Variant Perception & Thesis — Core investment case and where we disagree with consensus
Valuation — DCF model, Monte Carlo simulation, and scenario analysis
Catalyst Map — 12 confirmed events with probability-weighted price impacts
What Breaks the Thesis — Kill triggers, risk matrix, and permanent loss probability
Financial Analysis — Segment economics, margin drivers, and balance sheet quality
Competitive Position — Moat assessment, market contestability, and peer comparison

See related analysis in